A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Trial details
- Registry ID
- NCT06628947
- Drugs studied
- 100 μg KIO-301, 50 μg KIO-301
TrialRedline tracks 4 clinical trials sponsored by Kiora Pharmaceuticals, Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaNCT06628947 | 100 μg KIO-301, 50 μg KIO-301 | Recruiting | 2027-08Estimated |
| Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaNCT06825702 | KIO-104 | Recruiting | 2026-11Estimated |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial DefectsNCT05436288 | KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Completed | 2022-12-22Actual |
| A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune DiseaseNCT05629364 | KIO-101 | Terminated | 2024-01-09Actual |
Names as written in the registry records.